EMCURE PHARMACEUTICALS
Shark tank fame Namita Thapar to rake in Rs 127 crore through Emcure Pharma IPO
Shark Tank's Namita Thapar, who is part of Emcure Pharmaceuticals' promoter group, is set to earn approximately Rs 127 crore through the upcoming IPO. Thapar, who acquired shares in Emcure at an average price of Rs 3.44 each, will sell around 12.68 lakh shares through the OFS component of the IPO. With the upper price band set at Rs 1,008 per share, the stake sale is expected to yield about Rs 127 crore.
Emcure Pharmaceuticals IPO booked nearly 5x so far on Day 2. Check GMP and other details
Emcure Pharmaceuticals' IPO has been oversubscribed nearly three times as of Thursday, the second day of bidding. The bidding concludes on July 5. The categories reserved for NII and retail investors were subscribed the most at 13 times and 3.43 times, respectively.
Emcure Pharmaceuticals IPO fully subscribed on Day 1. Check GMP and other details
Emcure Pharmaceuticals' IPO attracts high demand from investors, with a price range of Rs 960-1008 per share. Analysts foresee business improvements and revenue growth potential in the global pharmaceutical market, supporting the company's expansion strategies.
Namita Thapar-backed Emcure Pharma IPO opens for subscription. Should you bid?
Emcure Pharma IPO: Emcure Pharmaceuticals IPO, with marquee investors like Goldman Sachs, offers a fresh equity issuance and OFS. Namita Thapar to earn Rs 127 crore through the stake sale. The company targets debt repayment and global expansion.
IPO Analysis: Emcure has better-listed pharma alternatives
Emcure Pharma, with its strong presence in gynaecology and HIV therapeutic areas, secured significant investments from anchor investors like HDFC Mutual Fund and ICICI Prudential Mutual Fund, showcasing immense market confidence in its upcoming IPO.
Bain Capital-backed Emcure Pharma mobilises Rs 583 cr from anchor investors
Emcure Pharmaceuticals has allocated 57.8 lakh equity shares to 48 funds at the upper end of the IPO price band, raising Rs 582.6 crore. The public subscription for the IPO will commence on July 3rd and conclude on July 5th.
Namita Thapar's Emcure Pharmaceuticals IPO opens on Wednesday. What GMP signals ahead of subscription
Emcure Pharmaceuticals' IPO opens for subscription on July 3rd with shares trading at a Rs 265 premium in the unlisted market. The IPO includes fresh equity shares worth Rs 800 crore and an Offer For Sale (OFS) of 1.14 crore shares. Priced at Rs 960-1,008 per share, investors can bid for 14 shares per lot. The company targets to raise Rs 1,952 crore at the upper price range.
Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issue
Emcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximately Rs 1,952 crore through the public offer. Market analysts indicate that the current GMP of the pharma company stands at Rs 260 in the unlisted market.
IPO Calendar: Primary market gears up for another robust week as 3 companies look to raise Rs 2,700 cr
Apart from the above 3 public offers, the Street will see as many 11 listings including that of Allied Blenders and Vraj Iron and Steel, which received healthy investors' response for their IPOs in the week gone by.
Emcure Pharma announces price band for Rs 1,952-crore IPO at Rs 960-1,008/share. Check GMP, other details
Emcure Pharmaceuticals has announced its initial public offering (IPO) with a price band of Rs 960 to Rs 1,008 per equity share. The subscription for the IPO will open on Wednesday, July 3, and close on Friday, July 5. The floor price and cap price of the issue are set at 96 times and 100.80 times the face value of the equity shares, respectively.
Bain Capital-backed Emcure Pharma to float IPO on July 3
Emcure Pharmaceuticals, backed by Bain Capital, is set to launch its IPO on July 3. The IPO includes fresh equity shares issuance and Offer of Sale. Proceeds will be used for debt payment and corporate purposes.
Ola Electric, Emcure Pharma get Sebi nod for IPOs, setting stage for big listings
The Bengaluru-based company had filed its draft prospectus with Sebi in December last year. The issue comprises a fresh equity sale of Rs 5,500 crore and an offer-for-sale (OFS) of 95.2 million shares.
Emcure Pharmaceuticals receives SEBI nod for its IPO launch
Emcure Pharmaceuticals received SEBI nod for IPO launch after filing DRHP in December 2023. The IPO includes equity shares and an Offer of Sale by promoters. Proceeds will be used for debt payment. Emcure Pharmaceuticals is renowned for its global marketing of pharmaceutical products.
Expert panel to soon weigh plan to use generics for prescription drugs
An expert committee is set to discuss the feasibility of allowing generic substitutions for prescription drugs in India. The proposal has sparked a disagreement between the Indian Pharmaceutical Alliance (IPA) and the All India Drug Action Network (AIDAN). The IPA opposes the idea, arguing that it would lead to a surge of demand from trade channels, such as general pharmacy stores, which would not benefit patients.
IPO season is back with more than 2 dozen companies chasing Rs 30,000 crore
India's primary market anticipates a wave of IPOs with over two dozen companies planning to raise ₹30,000 crore. Investor confidence is high with the Modi government's return for a third term, ensuring stable governance and policies.
Emcure and its subsidiary Gennova settle legal dispute with HDT Bio over mRNA technology
Emcure Pharmaceuticals and its subsidiary Gennova have resolved all legal disputes with US-based HDT Bio Corp. The parties have entered into a long-term agreement to develop mRNA vaccines against various infectious diseases in India and other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT's patented mRNA vaccine technology in multiple fields
Pad up, there's a brand new deal street in town
Cricketers have signed at least half a dozen endorsement, investment, and collaboration deals during the Indian Premier League (IPL) over the past two-three weeks. MS Dhoni has been signed by nutrition startup Explosive Whey, French carmaker Citroen, and Emcure Pharmaceuticals. Virat Kohli has collaborated with Philips for a limited-edition, co-designed beard trimmer, while Yashasvi Jaiswal has been signed by wearables brand boAt.
Emergency healthcare startup Medulance raises $3 million
New Delhi-based startup Medulance has raised funds after running as a profitable bootstrapped company for six years. This round also saw participation from investors such as Dexter Capital, Boat founder Aman Gupta, and Emcure Pharmaceuticals’ executive director Namita Thapar.
‘Shark Tank India’ judge Namita Thapar silences trolls who claimed she succeeded with ‘daddy’s money’
The entrepreneur, who recently held an ‘Ask Me Anything’ session on Reddit, was initially taken aback when a Reddit user attacked her personally, stating that she would be nowhere without the support of her father Satish Mehta, the founder of Emcure Pharmaceuticals.
Load More
